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Abstract. This study sought to identify a single molecule capable of managing all three
manifestations of metabolic syndrome–hyperglycaemia, dyslipidaemia and hypertension. Two
Protein Data Bank (PDB) depositions were selected and used to establish the baseline aﬃnity
that any designed molecule in this study should ideally exceed in order to be considered
for further optimisation. These were PDB depositions 3VN2 and 2P54 describing the bound
co-ordinates of the Peroxisome Proliferator Activated Receptor (PPAR)𝛾 partial agonist and
Angiotensin II Receptor (Ang(II)R) blocker telmisartan and of the experimental PPAR𝛼
ﬁbrate agonist GW590735 bound to their respective cognate receptors. These small molecules
were extracted from their cognate receptors, docked into their non-cognate counterparts,
conformational analysis performed, and the optimal conformers were selected as template
scaﬀolds in two parallel processes. The ﬁrst was a fragment based de novo approach. Here,
molecular moieties from the optimal telmisartan and GW590735 scaﬀolds modelled in their
non-cognate targets and considered critical to binding were identiﬁed and modelled, in order to
produce seed structures capable of sustaining molecular growth at user-directed sites designated
as H.spc atoms subsequent to their being docked within the non-cognate Ligand Binding
Pockets (LBPs). The second approach was a Virtual Screening (VS) exercise. Here, the optimal
telmisartan and GW590735 conformers were submitted as query molecules to VS databases
both individually and in the form of a consensus pharmacophore. This VS exercise identiﬁed
structurally diverse molecules which were electronically and spatially similar to the queries and
whichwere capable of modulating the target receptors. Themolecular cohorts identiﬁed through
both VS and the de novo approaches were ﬁltered for Lipinski Rule compliance. The molecules
that survived ﬁltering were then re-docked into the non-cognate PPAR𝛼 and/or 𝛾_LBPs,
conformational analysis re-performed and the aﬃnity of the optimal conformer measured for
its cognate receptor quantiﬁed. Comparison was made to the baseline and non-cognate receptor
aﬃnities previously established, and the molecules exhibiting dual aﬃnities exceeding baseline
values were selected for further optimisation. The use of the “tried and tested” Ang(II)R blocker
and ﬁbrate scaﬀolds as templates predisposes to the identiﬁcation of novel structures devoid of
unacceptable toxicity.
Keywords: PPAR, Structure-Multiple Activity Relationships
1. Introduction
PPARs are ligand-activated transcription factors. They belong to the nuclear hormone receptor
superfamily, and comprise three subtypes: PPAR𝛼, PPARγ, and PPAR𝛽/𝛿. Speciﬁcally, PPAR𝛼
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activation results in triglyceride level reduction. Furthermore, it has been demonstrated that
PPAR𝛼 is involved in in glucose homeostasis and the development of insulin resistance [1].
Activation of the PPAR𝛽/𝛿 receptor results in modiﬁcation of the body’s energy fuel preference
from glucose to fat [2]. The PPAR𝛾 subtype is a strong inducer of adipogenesis and is involved
in glucose metabolism [1]. This means that the PPAR family of nuclear receptors as a whole is
a regulator of energy homeostasis and metabolism. PPAR agonism consequently has potential
in a wide spectrum of pathologies including adipocyte diﬀerentiation, cancer, diabetes, dys-
lipidaemia, inﬂammation, lung diseases, neurodegenerative disorders, reproductive disorders,
obesity and pain.
Quite a number of ligands, both natural and synthetic, are able to activate the PPAR receptor;
these aremostly used in the treatment of glucose and lipid disorders. Literature indicates that, the
Polyunsaturated Fatty Acids (PUFAs) 𝛾-linolenic, eicosatrienoic, dihomo-𝛾-linolenic, arachi-
donic acid and eicosapentaenoic acid (EPA) interact most eﬃciently with PPAR𝛾 followed by
PPAR𝛽/𝛿. With respect to PPAR𝛼, PUFAs do not appear to bind any better than saturated
and monounsaturated FAs with the same carbon lengths. EPA may function as the natural
endogenous ligand of the PPARs owing to the fact that it shows promiscuity, binding well to all
the PPAR subtypes [3]. An exemplar of an endogenous ligand for PPAR𝛾 is the oxidized fatty
acid 13-hydroxyoctadeca-9,11-dienoic acid (13-HODE).
The bile pigment bilirubin was recently identiﬁed as a PPAR𝛼 agonist at the PPAR𝛼 receptor.
It was shown to reduce both glucose and body fat levels when in rodent experiments. This
explains why increased bilirubin levels such as occurs in patients suﬀering from Gilberts Syn-
drome appears to have a protective eﬀect on the vascular system [4].
The main PPAR𝛾 synthetic full agonists studied to date were the thiazolidinedione (TZD)
insulin-sensitizing drugs (e.g. rosiglitazone and pioglitazone) which were withdrawn from the
market due to their pharmacovigilance identiﬁed undesired adverse eﬀects such as weight gain,
oedema [5], bone loss and congestive heart failure [6].
Telmisartan was designed and developed as an Angiotensin II type 1 Receptor (Ang(II)R)
Blocker and consequently as an antihypertensive agent. Its promiscuity at PPAR𝛾 was co-
incidental and its allied beneﬁcial clinical consequences serendipitous. Its partial agonism of
PPAR𝛾 is of utility in the management of cardiometabolic disorders and Type 2 Diabetes
Mellitus [7].
The experimental inverse agonist at the PPAR𝛾 receptor SR10171 has been associated with
the advantage of normalizingmetabolic parameters whilst also increasing the turnover of trabec-
ular and cortical bone. This is an important ﬁnding owing to the fact that the TZDs are known to
cause osteoporosis as a side eﬀect. The bone protective ability of SR10171 has been explained
on a molecular level. Speciﬁcally it has been attributed to the interactions forged between
SR10171 and the PPAR𝛾_LBP where it blocks the activity of phosphorylated Ser273 which is
associated with osteoclastic activities but not phosphorylated Ser112 that has osteoblastic eﬀects
[8].
The synthetic ﬁbrates which are a class of triglyceride lowering drugs are ligands for PPAR𝛼
and are used in the treatment of hypertriglyceridaemia [5]. The active metabolites of the ﬁbrates
show preferential binding to the PPAR𝛾 receptor subtype, a 10-fold selectivity over the PPAR𝛼
receptor subtype [1].
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The multi-target approach is particularly relevant with the PPARs. Given that PPAR𝛼 ago-
nism is associated with dislipidaemia management, and that PPAR𝛾 agonists have demonstrably
been shown to have a potent hypoglycaemic eﬀect, the development of dual 𝛼 and 𝛾 agonists
is particularly interesting owing to the fact that dyslipidaemia and diabetes are commonly co-
morbid. The fact that the Ang(II)R blocker telmisartan is known to bind to, and act as an agonist
at PPAR𝛾 , makes the premise of dual PPAR 𝛼 and 𝛾 agonism even more relevant owing to the
fact that dual agonists bearing the sartan scaﬀold could, potentially, target the diabetes, hyper-
cholesterolaemia, and hypertension characteristic of the highly prevalent metabolic syndrome.
2. Methodology
A total of 70 crystallographic depositions describing PPAR receptor isoforms in the apo- and
holo- form were identiﬁed in the PDB at the time of study (Nov 2012). The suitability of each
PDB crystallographic deposition was assessed for inclusion. A total of 67 PDB entries with
resolution of up to 3Å were considered acceptable.
The following crystallographic depositions were chosen as baseline for this study; 3VN2 [9]
describing the bound co-ordinates of the partial agonist telmisartan to the PPAR𝛾_LBP, 2P54
[10] describing the experimental ﬁbrate GW590735 bound to PPAR𝛼 and 2VST [11] where the
endogenous ligand 13-hydroxyoctadecadienoic acid (13-HODE) is bound to PPAR𝛾 . Another
pdb crystallographic deposition, 4ZUD [12] describing the bound co-ordinates of olmesartan to
the Ang(II)R was also used in order to assess whether the PPAR𝛼 and 𝛾 modulators identiﬁed
in this study through the de novo and Virtual Screening (VS) drug design processes, would also
be able to modulate the Ang(II)R and consequently validate the hypothesis of a single entity
capable of managing metabolic syndrome. PROCHECK® [13] was used in order to assess the
integrity of these selected depositions.
Molecular modelling was carried out in Sybyl-X® [14]. The small molecules bound to 67
recruited holo- systems were extracted from their LBP and their aﬃnity for their respective
LBP quantiﬁed in X-SCORE® [15]. This allowed calculation for an average LBA (pKd) for
each PPAR subtype.
The partial PPAR𝛾 agonist and Ang(II)R blocker telmisartan and the PPAR𝛼 agonist
GW590735 were the template molecules used in this study. These were docked into their non-
cognate PPAR_LBPs and conformational analysis carried out in Sybyl-X® [14]. The optimal
conformer in each case was selected based on a combination of high LBA (pKd) and low
LBE (Kcalmol−1) based on the premises of high aﬃnity and molecular stability. These optimal
conformations were used in parallel processes.
3. de novoDrug Design
In the de novo drug design process, the optimal telmisartan and GW590735 conformers identi-
ﬁed through conformational analysis, were used as starting scaﬀolds for seed structure design.
Five seeds, two deriving from the telmisartan scaﬀold, and three deriving from the GW590735
scaﬀold were modelled in Sybyl-X® [14]. Seed design was guided by two sources of data;
Structure Activity Relationships data available in the literature and critical interactions forged by
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(i) optimal conformation of 
telmisartan subsequent to 
docking in PPARα
 (ii) TELMS1
 
(iii) TELMS2 
Figure 1: Modelled seed structures derived from the telmisartan scaﬀold (i) the optimal telmisartan conformer in
the non-cognate PPAR𝛼_LBP (2P54); (ii) TELMS1 shows the conserved part of the biphenyl moiety in a blue box;
(iii) TELMS2 shows in a blue box the preserved part of the nitrogen substituted fused 5-membered ring. Structures
rendered in Accelrys® [18].
the small molecules in the respective LBP as elucidated through the generation of 2D topology
maps as generated in PoseView® [16]. In each case, molecular growth was user directed. This
means that novel moiety introduction was allowed at pre-designated growing sites, modelled
in Sybyl-X® [14] through the assignment of H.spc hydrogen atoms (highlighted in red font
in Figures 1 and 2 respectively) which were recognised by the LINK and GROW modules of
LigBuilder® [17] as appropriate anchorage points.
The POCKET module of LigBuilder® version 1.2 [17] was used for LBP mapping and
general pharmacophore generation. PDB crystallographic depositions 3VN2 and 2P54 [9, 10]
describing the bound co-ordinates of telmisartan bound to PPAR𝛾 and of GW590735 bound to
PPAR𝛼 were used to generate LBP maps and general pharmacophoric structures that described
the pharmacophoric space circumscribed by telmisartan and GW590735 when these were
docked in their cognate and non-cognate LBPs. The surface volume (Å3) of each generated
LBP map was quantiﬁed in UCSF Chimera® [19].
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(ii) GW5S1
 
(i) optimal conformation of  
GW590735 subsequent to 
docking in PPARγ
 
        
(iv) GW5S3
 
(iii) GW5S2
Figure 2: Modelled seed structures derived from the GW590735 scaﬀold (i) the optimal GW590735 conformer in
the non-cognate PPAR𝛾_LBP (3VN2); (ii) GW5S1 and (iii) GW5S2 preserved the central O-linked spacer portion;
(iv) GW5S3 conserved the terminal portions of the molecule (the dotted part was removed). Structures rendered in
Accelrys® [18].
Both telmisartan based seed structures, TELMS1 and TELMS2 and two out of three
GW590735 based seed structures speciﬁcally GW5S1 and GW5S2 were, as depicted in Figures
1 and 2 designed to sustain terminal growth. For all of these seed structures, the GROW
module of LigBuilder® version 1.2 [17] was invoked to drive the de novo design process.
The GW590735 based seed structure GW5S3 was essentially composed of two disconnected
molecular fragments. For this seed structure de novo molecular growth was sustained in the
LINK module of LigBuilder® version 1.2 [17]. Execution of the GROW and LINK algorithms
resulted in the elaboration of a series of molecules that required further schematic organization.
Implementation of the PROCESS algorithm of LigBuilder® version 1.2 [17] for each molec-
ular cohort that was generated for each seed structure resulted in the creation of a molecular
database that contained molecules which were segregated according to pharmacophoric simi-
larity and which were ranked according to LBA (pKd). The molecular databases also contained
physicochemical information which included general formula, molecular weight, clogP, and a
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chemical score that was indicative of synthetic feasibility. The contents of each generatedmolec-
ular database (n=5) for each of the modeled seed structures considered in this study were further
ﬁltered using Lipinski rule compliance [20] as inclusion criteria. Five molecules were selected
from each molecular cohort (n=5). Selection was made according to binding aﬃnity and clogP
values. Molecules of varying clogP were selected, making sure that a spectrum of molecules
whose clogP was skewed towards hydrophilicity and lipophilicity respectively was included.
Speciﬁcally, molecules with clogP values that ranged from 1 to ≤4 were considered to be
mostly hydrophilic and therefore more likely to be targeted for central compartment associated
conditions, whereas molecules with clogP values that ranged from 4 to≤5 were considered to be
mostly lipophilic and consequently able to target peripheral compartment associated conditions
[21]. The chosen molecules were then subjected to conformational analysis in Sybyl-X® [14].
Speciﬁcally, all the selected structures deriving from the seed structures TELMS1 and TELMS2
were docked into the PPAR𝛾_LBP (pdb ID 3VN2) while selected structures deriving from
GW5S1, GW5S2 and GW5S3 were docked into the PPAR𝛼_LBP (pdb ID 2P54). In each case,
the best conformer was chosen, as previously explained, based on having a combination of
highest LBA (pKd) and lowest LBE (Kcalmol−1). The LBA (pKd) of the best conformers were
then compared to the precalculated values, speciﬁcally the average aﬃnity of all the holo-
systems calculated in the ﬁrst part of the study, as well as to the aﬃnities of telmisartan and 13-
HODE for the PPAR𝛾_LBP and GW590735 for the PPAR𝛼_LBP respectively (refer to Table 2
in results section).
The critical interactions of the optimal conformations of the selected molecules with their
corresponding receptor were visualised in PoseView® [16]. Their hydrophilic and hydrophobic
interactions were then compared to those obtained through similar analysis of the pdb crystal-
lographic depositions that were used as baselines for this study speciﬁcally 3VN2 [9] and 2P54
[10] describing the bound co-ordinates of telmisartan with PPAR𝛾 and GW590735 with PPAR𝛼
respectively. This process was carried out in the interest of identifying dual modulators for the
PPAR𝛾/𝛼 subtype.
4. Virtual Screening
The optimal telmisartan and GW590735 conformers obtained subsequent to docking into the
non-cognate PPAR𝛼 and 𝛾_LBPs were submitted to the database ViCi® [22] for the identiﬁca-
tion of sterically and electronically similar structures. MONA®, [23], a cheminformatics plat-
formwhich facilitates compound library processing was used in order to ﬁlter the twomolecular
cohorts obtained from the molecular database ViCi® [22] for Lipinski Rule compliance.
Sybyl-X®’s v1.1 [14] Surﬂex-dock𝑇𝑀 algorithm was then invoked in order to generate
two protomols for the pdb crystallographic depositions that were used as baseline for this
study. The holo- complexes pdb ID 3VN2 [9] describing the bound co-ordinates of telmisartan
with PPAR𝛾 , and pdb ID 2P54 [10] describing the bound co-ordinates of GW590735 with
PPAR𝛼 were successively loaded into Sybyl-X® v1.1 [14]. All unnecessary moieties including
the bound small molecule (telmisartan and GW590735 respectively), and non-critical water
molecules were removed consequently creating two apo- proteins. A set-up ﬁle for each
protomol was created; this contained the necessary information to guide small molecule docking
to the protomol. The ﬁltered molecular cohorts emanating from MONA® [23] when the best
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conformers of telmisartan and GW590735 in the PPAR𝛼 and 𝛾_LBPs respectively together with
nine decoy molecules were docked back into their respective protomols and ranked in order of
aﬃnity. 10 molecules from each cohort were chosen based on favorable scores obtained from
the various methods employed and physicochemical properties.
Two consensus pharmacophores were generated in LigandScout® 4.0 [24]. The ﬁrst was an
average of the telmisartan co-ordinates as co-crystallised with PPAR𝛾 (pdb ID 3VN2) [9] and its
optimal conformer docked within the PPAR𝛼_LBP. The second was an average of GW590735
as those of its co-crystallised within the PPAR𝛼_LBP (pdb ID 2P54) [10] and its optimal
conformer docked within the PPAR𝛾_LBP respectively. These consensus pharmacophores were
submitted sequentially to ZINCPharmer® [25]. During the VS process using ZINCPharmer®
[25], a number of stringent ﬁlters were enforced in order to allow for molecular optimization by
structural modiﬁcation, while remaining within Lipinski’s [20] recommendations for ensuring
bioavailability. Other criteria proposed by Veber and his co-workers [26] suggest that orally
bioavailable molecules should have 10 or fewer rotatable bonds and a low polar surface area
(<140Å2) or total hydrogen bond count (<12 hydrogen bond donors and acceptors). Therefore,
a molecular weight of 200-250 and 1-3 rotatable bonds for the ﬁrst consensus pharmacophore
submitted to ZINCPharmer® [25] were used as ﬁltering criteria, however for the second consen-
sus pharmacophore submitted, the criteria for molecular weight had to be widened to 200-500.
The molecular cohorts identiﬁed from the ZINCPharmer® [25] database were read into the pre-
viously generated protomols. Speciﬁcally, the Lipinski rule compliant molecules obtained after
submitting the molecular pair telmisartan:optimal telmisartan conformer in PPAR𝛼 consensus
pharmacophore were docked in the protomol generated for 3VN2 [9] whereas the molecules that
were obtained after submitting the GW590735:optimal GW590735 in PPAR𝛾 consensus phar-
macophore pair to ZINCPharmer® [25] were docked in the protomol created for 2P54 [10] in
Sybyl-X®’s [14] docking suite, respectively. Each molecular cohort subsequent to docking into
its respective protomol, the molecules were ranked in order of binding aﬃnity to the protomol.
Three molecules from each molecular cohort were chosen based on favorable scores and
physicochemical properties.
Molecules that predisposed towards dual PPAR𝛾/𝛼 modulation were docked into the
apo- Ang(II)R_LBP as described in pdb crystallographic deposition 4ZUD [12] where the
bound small molecule olmesartan is cognate. Conformational analysis was performed for each
selected molecule and the optimal conformer identiﬁed, again based on high LBA (pKd) and
low LBE (Kcalmol−1). These results were compared to the LBA (pKd) of olmesartan to its
cognate Ang(II)R as described in pdb crystallographic deposition 4ZUD [12] and to the LBA
(pKd) of telmisartan subsequent to it being docked in the Ang(II)R. 2D topology maps of the
critical interactions of the optimal conformations of the selected molecules within the Ang(II)R
were generated in PoseView® [16]. Their hydrophilic and hydrophobic interactions were
then compared to those obtained through similar analysis of pdb crystallographic deposition
4ZUD [12] that was used as baseline for this study and to the interactions forged by the
optimal telmisartan conformer when this was docked into the Ang(II)R as described in pdb
crystallographic deposition 4ZUD [12].
The potential of the selected molecules to act as PPAR𝛾 inverse agonists in a manner anal-
ogous to the experimental molecule SR10171 was also assessed [8]. To this aim, when these
were docked into the PPAR𝛾_LBP, the key interactions forged between them and the amino
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Table 1: The surface volume in Å3 occupied by the molecules that were selected as baseline in this study, telmisartan
and GW590735 in the cognate and non-cognate PPAR𝛼 and 𝛾_LBPs quantiﬁed in UCSF Chimera® [19].
Surface Volume (Å3)
Cognate Non-cognate Protomol
Telmisartan 640.5 646.2 -
Protomol (telmisartan in cognate PPAR𝛾_LBP as described
in pdb crystallographic deposition 3VN2)
- - 1273
GW590735 646.6 626.8 -
Protomol (GW590735 in cognate PPAR𝛼_LBP as described
in pdb crystallographic deposition 2P54)
- - 1145
acids lining the LBP were assessed in order to identify whether or not any interactions were
being forged between these molecules and phosphorylated Ser273 and Ser112.
Chosen molecules which apart from being able to act as dual PPAR𝛾/𝛼 modulators also
showed LBAs (pKd) similar to those of olmesartan and telmisartan towards the Ang(II)R were
submitted to the webserver ProTox [27] in order to predict their oral toxicity in rodents.
5. Results and Discussion
As indicated previously, a total of 70 apo- and holo- PPAR related crystallographic depositions
were identiﬁed from the pdb at the time of study (November 2012). 67 of these were identiﬁed as
suitable for this study; a resolution of up to 3Åwas considered suitable for a pdb crystallographic
deposition to be included in the study. All four Ramachandran plots generated in PROCHECK
[13], for the pdb crystallographic depositions that were chosen as baseline for this study had
most residues, that is more than 90%, in the most favoured regions of the plot which further
reinforced their suitability as template crystallographic depositions.
Comparison wasmade of the surface volume (Å3) of the LBPmaps generated in LigBuilder®
[17] when the cognate and non-cognate small molecules telmisartan and GW590735 were
docked. The fact that this volume remained largely constant across the board as shown in Table
1 implies the spatial similarity from a volume perspective of the two PPAR subtypes considered
and also of the magnitude of the two high aﬃnity ligands used as templates for this study. This
molecular volume similarity also bodes well for the design, as this study aims to do, of dual
PPAR 𝛾/𝛼 modulators and potentially established volume requirements for such molecules.
The volume of the protomol, the idealized LBP generated through identiﬁcation of the ener-
getically disfavoured space at the core of the PPAR subtypes, was of 1273Å3 and 1145Å3 for
PPAR𝛾 and PPAR𝛼 as described in pdb crystallographic depositions 3VN2 and 2P54 respec-
tively. These volumes are signiﬁcantly larger that the LBP maps described in LigBuilder® [4].
This is not surprising given that the algorithms in the two software programmes (LigBuilder®
and Sybyl-X®) used are not the same, and that they calculate diﬀerent variables. In the case
of LigBuilder® [17], calculation is made based on direct contact between the ligand and the
surrounding amino acids while in Sybyl-X® [14] the protomol is calculated as a function of
the energetically unsatisﬁed amino acids within a 0.5Å3 region of the docked ligand. The latter
necessarily describes a larger volume which represents a greater but not necessarily bioactive
space for design.
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The general structure of PPAR agonists is documented in the literature [28]; the general
structure of PPAR𝛼 speciﬁc ﬁbrates is also well documented [29]. Speciﬁcally, PPAR agonism
has been associated with the molecular existence of an acidic head group, a short linker to an
aromatic ring and a second linker to a cyclic tail which can be an aromatic or an aliphatic ring
system. Fibrates which are PPAR𝛼 speciﬁc agonists also fall into this broad generalisation.
The molecules designed de novo in this study, as well as those identiﬁed through VS which
complied with Lipinski’s Rules and that fell into a clogP range that predicted diﬀerent in vivo
distribution based on polarity, were analysed for conformity to these documented structural
pre-requisites.
GW5S2_F2S115, generated de novo from the GW5S2 molecular cohort, seen in Figure
3(i), possesses an acidic head group linked to an aromatic centre and a tail that is not cyclic.
The naphthalene group with the butyl side chain in GW5S2_F2S115 is similar to the central
benzimidazole group with the propyl side chain of telmisartan.
Molecule 509 that was identiﬁed through VS using the online molecular database ViCi®
[22], seen in Figure 3(ii) when the best conformer of telmisartan in the non-cognate PPAR𝛼
was submitted as query molecule has an acidic group that lies centrally in the molecule. The
multiple aromatic rings that constitute structure 509 make it resemble molecule GW590735 that
was used as baseline in this study.
Molecule ZN4, shown in Figure 3(iii), that was identiﬁed through VS using the online molec-
ular database ZINCPharmer® [25], when the consensus pharmacophore generated between
the molecular pair GW590735:best GW590735 conformer in PPAR𝛾 was submitted as query
molecule also conforms to the general structure proposed for PPAR agonists. The quinolone
and benzothiazole groups in molecule ZN4 are similar to the two benzimidazole groups that
constitute telmisartan.
When the interactions forged between telmisartan and its cognate PPAR𝛾_LBP were com-
pared to those forged between the optimal GW590735 conformer and the non-cognate
PPAR𝛾_LBP, the following similarities were observed:
• A hydrogen bond arises between Tyr473 and the centrally located benzimidazole group
in telmisartan and the thiazole group in GW590735.
• Non-polar interactions arising from Cys285 and Met364 were observed with the acidic
head groups of both telmisartan and GW590735.
When the interactions forged between GW590735 and its cognate PPAR𝛼_LBP were com-
pared to those forged between the optimal telmisartan conformer and the non-cognate
PPAR𝛼_LBP, similar interactions were also observed. These included:
• Hydrogen bonds between the acidic head groups of both molecules and residues Tyr314,
His440 and Tyr464 of the PPAR𝛼_LBP.
• Non-polar interactions between Cys275, Cys276, Val332 and Met355 and the PPAR𝛼_LBP
were observed when both molecules were resident.
Molecule GW5S2_F2S115 (ref to Figure 3(i)) showed dual PPAR𝛾/𝛼 aﬃnity. Compound
GW5S2_F2S115 forged a hydrogen bond between a carbonyl group and Tyr473 similar to telmis-
artan. Another hydrogen bond was forged with Ser289 in the PPAR𝛾_LBP. His323 and Ser289
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Figure 3: 2D representation of (i) GW5S2_F2S115, (ii) structure 509 and (iii) molecule ZN4, generated through
VS using the online molecular database ZINCPharmer® [25] when the consensus pharmacophore derived from the
molecular pair GW590735: best GW590735 conformer in PPAR𝛾 was submitted as query molecule. Rendered in
Accelrys® [18].
were involved in hydrogen bonding interactions when interactions forged between PPAR𝛾 full
agonists were observed.
Non-polar interactions with Cys285 andMet364 were forged between GW5S2_F2S115 and the
PPAR𝛾_LBP. Hydrophobic interactions help to stabilise the PPAR𝛾_LBP and are similar to
those cited in the literature for interactions forged by partial agonists with the PPAR𝛾_LBP
[29]. These interactions were also forged when telmisartan was in its cognate PPAR𝛾_LBP.
When GW5S2_F2S115 was re-docked into the PPAR𝛼_LBP, hydrogen bonds with Ser280,
Tyr314, His440 and Tyr464 were forged between the selected molecule, and the PPAR𝛼_LBP.
Non-polar interactions with Cys275 and Met355 were also observed. These interactions were the
same as those observed when GW590735 was in its cognate PPAR𝛼_LBP as described in pdb
crystallographic deposition 2P54 [10].
Molecule 509 (ref to Figure 3(ii)) forged two hydrogen bonds; one between a basic carbonyl
and Cys275 (ref to Figure 6(i)) and the other located centrally in the molecule with Met355 of the
PPAR𝛼_LBP. Molecule number 509 forged polar interactions between a basic carbonyl group
and Cys285 and the other between the oxygen of an oxazole group in the molecule and His449
when this was docked in the PPAR𝛾_LBP. On the other hand, only one hydrogen bond was
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 Green dotted line Pi-stacked 
 Black dotted line Hydrogen Bond 
 Green smooth contour lines Hydrophobic 
 
 
Figure 4: Critical interactions forged by (i) the PPAR𝛾 partial agonist telmisartan and by (ii) the PPAR𝛼 experimental
ﬁbrate agonist GW590735 with the PPAR𝛾 and 𝛼_LBPs of pdb crystallographic depositions 3VN2 [9] and 2P54 [10]
respectively. Generated in PoseView® [16].
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Key: Colour Type of interaction 
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 Black dotted line Hydrogen Bond 
 Green smooth contour lines Hydrophobic 
Figure 5: 2D topology maps of molecule GW5S2_F2S115 docked in the (i) PPAR𝛾 and (ii) 𝛼_LBPs as described
in pdb crystallographic depositions 3VN2 [2] and 2P54 [3] respectively. Generated in PoseView® [13].
forged between the central benzimidazole group of telmisartan and Tyr473 within the cognate
PPAR𝛾_LBP.
Two pi-pi stacked interactions with residues Phe363 and Phe282 were forged betweenmolecule
number 509 and the PPAR𝛾_LBP as described in pdb crystallographic deposition 3VN2 [9]. The
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Figure 6: Critical contacts forged between molecule 509 identiﬁed through VS when the optimal telmisartan
conformer in the non-cognate PPAR𝛼_LBP was planted within the (i) PPAR𝛼 and (ii) PPAR𝛾_LBPs as described in
pdb crystallographic depositions 2P54 [10] and 3VN2 [9] respectively. Generated in Discovery Studio® [30].
pi-pi stacked interaction with the terminal benzene ring and Phe363 is similar to that observed
between telmisartan’s terminal benzimidazole and the PPAR𝛾_LBP. Non-polar interactions at
both molecule termini were observed with Phe282, Phe363 and Met364 similar to telmisartan in
the PPAR𝛾_LBP [2]. The similarity in the interactions forged by molecule 509 to telmisartan
in the PPAR𝛾_LBP may make this structure a partial agonist at the named receptor.
Reference is made to the molecular cohort identiﬁed through VS using the online molecular
database ZINCPharmer® [25] when consensus pharmacophore GW590735:optimal
GW590735 in the PPAR𝛾_LBP was submitted as a query molecule. The only identiﬁed
molecule, referred to as molecule ZN4 in this study, showed dual PPAR 𝛾/𝛼 aﬃnity. When
molecule ZN4 (ref to Figure 3(iii)) was docked in the PPAR𝛾_LBP, a conventional hydrogen
bond was forged between a central acidic nitrogen and Ser289. In telmisartan a similar hydrogen
bond between a basic nitrogen on the central benzimidazole group and Tyr473 was forged in
the cognate PPAR𝛾_LBP. Non-polar interactions with Met364 and Cys285 were forged, similarly
to the partial agonist telmisartan interactions in PPAR𝛾_LBP. A pi-pi stacked interaction with
Phe282 was also present, similar to the pi-pi stacked interaction forged between telmisartan’s
terminal benzimidazole and Phe363 lining the PPAR𝛾_LBP [9]. Docking of compound ZN4 into
the PPAR𝛼_LBP resulted in the forging of conventional hydrogen bonds with Tyr314 and Tyr464,
pi-sulfur interactions with Met330 and Met355 similar to the interactions forged by GW590735
and the cognate PPAR𝛼_LBP [10].
None of the chosen molecules that were selected as optimal and thus suitable for further
optimization, speciﬁcally GW5S2_F2S115 derived de novo from the GW5S2 molecular cohort,
molecule 509 identiﬁed through VS using the online molecular database ViCi® [22] when the
best conformer of telmisartan in PPAR𝛼 was submitted as query molecule and molecule ZN4
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Figure 7: Critical contacts forged between molecule ZN4 identiﬁed through VS when the consensus pharmacophore
derived from the molecular pair GW590735:optimal GW590735 conformer in the non-cognate PPAR𝛾_LBP was
submitted as query molecule docked within the (i) PPAR𝛼 and (ii) PPAR𝛾_LBPs as described in pdb crystallographic
depositions 2P54 [9] and 3VN2 [10] respectively. Generated in Discovery Studio® [30].
identiﬁed through VS using the searchable molecular database ZINCPharmer® [25] when the
consensus pharmacophore derived fromGW590735: best GW590735 conformer in PPAR𝛾 was
submitted as query molecule were shown to forge any interactions with phosphorylated Ser273
and Ser112.
The post-translational modiﬁcations occurring subsequent to ligand binding, that result in
dephosphorylation of Ser112 and Ser273 of the PPAR𝛾_LBP result in pro-adipocytic and insulin-
sensitizing eﬀects respectively [31]. The molecules identiﬁed in this study consequently do not
appear to have potential in the management of osteoporosis.
The premise of the design of novel structures with the functional ability to simultaneously
manage the three conditions; hypertension, hypercholesterolaemia and diabetes inherent to
metabolic syndrome must be addressed.
When there is excessive caloric intake, there is a metabolic overload that results in an increase
in triglyceride input which causes adipocyte enlargement. In obese, non-diabetic subjects, TG
storage and 𝛽-oxidation in muscle are normally maintained to prevent insulin resistance. How-
ever, upon further excessive caloric intake, adipocytes undergo hypertrophy with the resultant
increase in the secretion of macrophage chemoattractants. This results in a pro-inﬂammatory
state where TG deposition is impaired and lipolysis is increased; resulting in an increase in
circulating FFA and TG that accumulate in skeletal muscle, liver and 𝛽 -cells to form long chain
fatty acyl co-A esters that disrupt normal metabolic and secretory functions of these tissues. The
inﬂammatory response thus contributes to metabolic dysfunction in obesity [32].
In the case of PPAR𝛼, defective fatty acid metabolism can result in the development of non-
alcoholic fatty liver disease [33].
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Table 2: The LBAs (pKd) of telmisartan and GW590735 for their cognate and non-cognate receptors (red font) and
the LBAs (pKd) of 13-HODE and olmesartan. The average LBAs (pKd) calculated from the 3 holo- PPAR complexes
deposited on the pdb (Nov 2012) are included as a reference.
Preferred IUPAC name, rendered in
MarvinSketch 17.13 [36]
LBA (pKd)
PPAR isoform
𝛿 𝛾 𝛼 Ang(II)R
Average for all ligands in the PDB
crystallographic depositions considered
acceptable in this study
7.79 7.92 7.94
13-HODE (9Z,11E,13S)-13-hydroxyoctadeca-
9,11-dienoic
acid
5.86
Telmisartan 4’-{[4-methyl-6-(1-methyl-1H-1,3-
benzodiazol-2-yl)-2-propyl-1H-1,3-
benzodiazol-1-yl]methyl}-[1,1’-
biphenyl]-2-carboxylic
acid
9.26 7.16 7.66
GW590735 5.75 7.84
Olmesartan 4-(2-hydroxypropan-2-yl)-2-propyl-1-
{[2’-(1H-1,2,3,4-tetrazol-5-yl)-[1,1’-
biphenyl]-4-yl]methyl}-1H-imidazole-
5-carboxylic
acid
7.08
Cytokines such as TNF𝛼 cause a downregulation of PPAR𝛾 and related target genes which
result in excessive adipose tissue and obesity with its related problems. However, the use of
PPAR𝛾 agonists was shown to suppress local TNF𝛼 production [34].
This has to be kept in mind when designing novel molecules that might be able to modulate
the PPAR𝛾 and 𝛼 receptors especially, in the case of ﬁbrates that are predominant PPAR𝛼
agonists, whose metabolites show preferential binding to PPAR𝛾 .
Body weight and adiposity regulation by fenoﬁbrate is regulated by sexual dimorphism.
Oestrogen was found to compete with the co-activator binding site of PPAR𝛼, therefore inhibit-
ing the actions of PPAR𝛼 in obese females with functioning ovaries [35].
The two approaches adopted in this study, speciﬁcally de novo design and VS yielded 1
molecule and 2 molecules (GW5S2_F2S115, 509 and ZN4) respectively with the in silico
calculated aﬃnity attributes (molecule GW5S2_F2S115 LBA (pKd) for PPAR𝛾 = 9.45; LBA
(pKd) for PPAR𝛼 = 7.47; structure 509 LBA (pKd) for PPAR𝛾 = 8.44; LBA (pKd) for PPAR𝛼
= 7.73; molecule ZN4 LBA (pKd) for PPAR𝛾 = 7.46; LBA (pKd) for PPAR𝛼 = 7.72) that
predisposed towards dual PPAR𝛾/𝛼 agonism. These molecules were subsequently docked into
the Ang(II)R_LBP as described in pdb ID 4ZUD [11] in which the bound small molecule
was olmesartan. As previously outlined, telmisartan, and molecules GW5S2_F2S115, structure
509 and molecule ZN4 were docked into the olmesartan bound Ang(II)R_LBP and conforma-
tional analysis performed. This was done in order to assess the LBA of these molecules for
the Ang(II)R and assess their ability to also mitigate hypertension. The LBA of the optimal
conformer of each of the four molecules was selected as representative and their LBA selected
for comparison. Reference is made to Table 2 where it is evident that the optimal conformations
of molecules GW5S2_F2S115, structure 509 and molecule ZN4 bind to the Ang(II)R with an
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in silico calculated aﬃnity (pKd 6.51, 6.89 and 6.68) that is comparable to that of the optimal
conformation of telmisartan (pKd=7.66) at this locus.
Molecules GW5S2_F2S115 and molecule ZN4 showed predicted class IV oral toxicity
(harmful is swallowed). However, this result is comparable to that obtained for telmisartan.
Structure 509 exhibited class III oral toxicity in rodents (toxic if swallowed), which is com-
parable to the toxicity of olmesartan. The two baseline molecules 13-HODE and GW590735
showed class V and VI oral toxicities respectively and are therefore the least toxic.
The toxicity of the selected de novo and virtually identiﬁed molecules was, as previously
stated assessed using ProTox [27].These toxicity evaluations seem to indicate that
GW5S2_F2S115 and compounds 509 and ZN4 are toxic if orally ingested, a fact that would pose
serious limitations on the future investment value of these molecules. This toxicity assessment
must however be viewed in relation to that also made for telmisartan and olmesartan which
exhibit similar toxicity predictions and are in current clinical use. The implication consequently
is that these molecules would be suitable for oral administration – a premise that requires in
vivo validation.
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